Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

1
Player Avatar StockDocStan (< 20) Submitted: 9/7/2011 10:26:09 AM : Outperform Start Price: $91.91 BIIB Score: +33.14

The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.

Report this Post 2 Replies
Member Avatar ikkyu2 (99.32) Submitted: 6/15/2012 8:22:27 PM
Recs: 0

A buyout? At a 33% premium to market, today's buyout price is $50 billion. Which pharma company has that much cash sitting around?

Member Avatar Mega (99.96) Submitted: 6/17/2012 12:46:08 PM
Recs: 0

GlaxoSmithKlineBiogenIdec would be a good company name.

Featured Broker Partners


Advertisement